Krka, d. d. (WSE:KRK)

Poland flag Poland · Delayed Price · Currency is PLN
1,038.00
-22.00 (-2.08%)
Apr 28, 2026, 4:40 PM CET
38.77%
Market Cap 31.38B
Revenue (ttm) 8.61B
Net Income (ttm) 1.70B
Shares Out n/a
EPS (ttm) 55.74
PE Ratio 18.44
Forward PE 18.25
Dividend 35.03 (3.40%)
Ex-Dividend Date Jul 22, 2025
Volume 70
Average Volume 68
Open 1,032.00
Previous Close 1,060.00
Day's Range 1,030.00 - 1,042.00
52-Week Range 734.00 - 1,100.00
Beta 0.46
RSI 55.61
Earnings Date May 14, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabo... [Read more]

Sector Healthcare
Founded 1954
Employees 11,667
Stock Exchange Warsaw Stock Exchange
Ticker Symbol KRK
Full Company Profile

Financial Performance

In 2025, Krka, d. d.'s revenue was 2.04 billion, an increase of 6.89% compared to the previous year's 1.91 billion. Earnings were 403.24 million, an increase of 12.96%.

Financial numbers in EUR

News

Krka, d. d. Earnings Call Transcript: Q4 2025

Record revenue and net profit were achieved in 2025, driven by strong growth across key markets and product launches. The outlook for 2026 projects continued sales and profit growth, with increased investment in capacity and innovation.

3 months ago - Transcripts